Cerus (NASDAQ:CERS) COO Vivek Jayaraman Sells 34,094 Shares of Stock

Cerus Corporation (NASDAQ:CERS) COO Vivek Jayaraman sold 34,094 shares of Cerus stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $2.01, for a total transaction of $68,528.94. Following the sale, the chief operating officer owned 1,912,874 shares of the company’s stock, valued at approximately $3,844,876.74. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cerus Price Performance

Cerus stock opened at $1.93 on Tuesday. The company’s 50 day simple moving average is $2.31 and its 200-day simple moving average is $1.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. Cerus Corporation has a 1 year low of $1.12 and a 1 year high of $2.96. The company has a market capitalization of $370.89 million, a price-to-earnings ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The firm had revenue of $64.58 million during the quarter, compared to analysts’ expectations of $59.31 million. As a group, equities research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CERS. Wall Street Zen lowered Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. TD Cowen reiterated a “buy” rating on shares of Cerus in a report on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

More Cerus News

Here are the key news stories impacting Cerus this week:

• Neutral Sentiment: Short-interest data flagged an apparent increase for the March 9 reporting period but shows 0 shares and reports a days-to-cover of 0.0 — the print looks incorrect or incomplete and should be treated as unreliable until exchanges update filings.
• Neutral Sentiment: Analysts overview: The Globe and Mail ran a piece discussing analysts’ views on Cerus alongside peers (Fennec). That coverage provides context but does not appear to contain new company-specific catalysts. Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)
• Negative Sentiment: Insider selling: several insiders disclosed sales between Mar. 5–9 that reduce insider ownership by low-single-digit to mid-single-digit percentages. Notable filings: CEO William Mariner Greenman sold 78,187 shares (~$157k). COO Vivek Jayaraman sold 34,094 shares (~$68.5k). CFO Kevin D. Green sold 27,796 shares (~$55.9k). Director Richard J. Benjamin reported multiple sales (61,233; 40,426; 24,235 shares) at ~$2.06–$1.88 across Mar. 5–9. Insider Chrystal Jensen sold 30,845 shares (~$62k). Collectively, these are meaningful in signaling added supply and may weigh on sentiment even if sales were for personal/liquidity reasons. CEO filing: http://www.sec.gov/Archives/edgar/data/1020214/000137725826000004/xslF345X05/ownership.xml COO filing: http://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/xslF345X05/ownership.xml Chrystal Jensen filing: http://www.sec.gov/Archives/edgar/data/1020214/000156425226000004/xslF345X05/ownership.xml Richard Benjamin filings: http://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/xslF345X05/ownership.xml CFO filing: http://www.sec.gov/Archives/edgar/data/1020214/000145935126000005/xslF345X05/ownership.xml

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CERS. Cibc World Markets Corp purchased a new stake in Cerus during the 4th quarter worth approximately $25,000. MML Investors Services LLC purchased a new position in Cerus in the 4th quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd boosted its position in Cerus by 68.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 7,603 shares during the period. Bingham Private Wealth LLC acquired a new position in shares of Cerus in the fourth quarter worth $40,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Cerus in the third quarter worth $31,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.